As reported by the National Health Executive, zero tariffs on UK pharma and extra funding will bring faster NHS access to new treatments
The UK has secured a world-first trade deal with the United States that removes all tariffs on British pharmaceutical exports and protects tariff-free access for medtech. The agreement is part of the UK-US Economic Prosperity Agreement and is expected to trigger a new wave of life sciences investment.
Ministers say the deal will translate into real benefits for patients, with tens of thousands expected to gain faster access to life-saving medicines and more resilient supply chains across the NHS.
The government is also increasing funding for innovative treatments by 25 per cent, marking the first major uplift in more than two decades. The move will give NICE greater flexibility to approve cutting-edge drugs that may previously have been rejected on cost grounds, including new cancer therapies and medicines for rare conditions.
Pharmaceutical giants such as Moderna, Bristol Myers Squibb and BioNTech have already announced multibillion-pound investments in the UK, a sign of growing confidence in Britain’s aim to become Europe’s leading life sciences economy by 2030.
Be the first to comment